ECO Animal Health Group PLCLSE: EAH

ECO Animal Health Group: New Aivlosin® marketing authorisations

· Issued by ECO Animal Health Group PLC via RNS

Summary by 6ix AI

ECO Animal Health Group plc, which develops and markets branded veterinary products for livestock, received new marketing authorisations (approvals to sell) for its antibiotic Aivlosin in Paraguay and Honduras, plus import permits for Saudi Arabia and Oman.

Key details

  • Aivlosin is ECO's antibiotic for treating respiratory and intestinal diseases in pigs and poultry.
  • Commercial sales of Aivlosin have already begun in Saudi Arabia and Oman, and ECO says they will largely use its existing commercial infrastructure for Aivlosin.
  • Saudi Arabia is being accessed through a special import license. ECO says Saudi Arabia is a poultry market growing at 5.8% annually and is responsible for over half of the region's animal health market.

6ix AI wrote this summary from the release below and checked it against the release.

Eco Animal Health Group PLC
18 November 2026

18 November 2026

ECO Animal Health Group plc

(“ECO” or the “Company”)

New marketing authorisations received for Aivlosin®

ECO Animal Health Group plc (AIM: EAH), a leading global animal health company developing and marketing branded veterinary products to improve livestock productivity and welfare, announces further expansion of Aivlosin®, its market leading antibiotic for the treatment of respiratory and intestinal diseases in pigs and poultry, with new authorisations in Paraguay and Honduras and import permits providing accelerated routes to markets in Saudi Arabia and Oman.

Commercial sales have already begun in Saudi Arabia and Oman, and will largely leverage the Group’s existing commercial infrastructure for Aivlosin®. Saudi Arabia is a substantial poultry market, growing at 5.8% annually and responsible for over half of the region’s animal health market, providing a meaningful commercial opportunity and is being accessed via a special import license.

David Hallas, Chief Executive Officer of ECO Animal Health, said: “These new marketing authorisations will provide an opportunity for us to expand our market leading Aivlosin® franchise, extending our reach into Latin America and establishing a foothold in a key poultry market in the Middle East. Coupled with recent progress in geographies such as South and South East Asia, these authorisations highlight ECO’s growth potential through our core business in addition to our innovative R&D pipeline.”

-Ends-

Contacts

ECO Animal Health Group plc

David Hallas (Chief Executive Officer)

Christopher Wilks (Chief Financial Officer)

020 8447 8899

ICR Healthcare (Financial PR)

Mary-Jane Elliott

Jessica Hodgson

Phillip Marriage

020 3709 5700

Singer Capital Markets (Nominated Adviser & Joint Broker)

Jen Boorer

Sara Hale

James Fischer

020 7496 3000

Panmure Liberum (Joint Broker)

Emma Earl

Will Goode

Mark Rogers

Rupert Dearden

020 3100 2000

Equity Development

Hannah Crowe

Matt Evans

020 7065 2692

About ECO Animal Health

ECO Animal Health (AIM: EAH) is a leading global animal health company, developing and marketing branded veterinary products that optimise livestock wellbeing and productivity.

The Group’s proprietary lead product, Aivlosin® is a market leading antibiotic for the treatment of respiratory and intestinal diseases in pigs and poultry, distributed to over 70 markets through an established commercial platform.

ECO Animal Health is also investing in the next generation of animal health products through a self-funded R&D pipeline, with a particular focus on prevention and vaccines. The first product from ECO’s pipeline, ECOVAXXIN® MS, a poultry vaccine targeting Mycoplasma synoviae infection, was commercially launched in the EU in July 2026.

Headquartered in the UK, with a global presence, ECO Animal Health employs over 200 people worldwide.

View the Group’s website or LinkedIn page for further information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ECO Animal Health Group PLC on 6ix

Earlier from ECO Animal Health

All ECO Animal Health news releases